Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.
Subscribe to our newsletter and stay updated on the latest developments and special offers!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results